Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Biden outlines 'Moonshot' initiatives to fight cancer

Published 06/29/2016, 12:45 PM
Updated 06/29/2016, 12:50 PM
© Reuters. U.S. Vice President Joe Biden delivers remarks at a conference of the Center for New American Security think tank in Washington

By Toni Clarke

WASHINGTON (Reuters) - U.S. Vice President Joseph Biden on Wednesday announced plans as part of the administration's "Cancer Moonshot" initiative, aimed at speeding development of treatments by cutting bureaucracy and easing collaboration between scientists, industry, patients and government.

Speaking at a cancer summit at Howard University in Washington, Biden made an impassioned plea for increased urgency in the fight against cancer. The event was part of a national day of action involving hundreds of researchers, patient advocates and data experts across the country.

Biden's son Beau died last year at age 46 from brain cancer, something Biden said helps inform his passion for the project.

"I believe we can do in the next five years what would normally take 10 years," he said. "Time matters, days matter, minutes matter."

Among proposals intended to bypass inefficiency at the federal level, he announced the formation of an Oncology Center of Excellence at the Food and Drug Administration, which will coordinate and review all of FDA cancer treatments.

It comes as scientific advances in diagnostics allow for greater tailoring of drugs to an individual's genetic profile. It is the first of four potential centers proposed under a bill moving through Congress.

Under the existing review system, companies submit products to different divisions of the agency depending on whether it is a drug, device or biologic, a drug made from living cells. A treatment that combines a drug and a diagnostic device could get reviewed on different timelines.

"We are moving into a very complicated area in oncology where drugs and devices and biologics are going to be used in combination or sequentially," Dr. Richard Pazdur, the FDA's cancer drug director, said in an interview.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Pazdur will oversee the establishment of the center and act as its director for the next 120 days, with the potential for the position to be renewed. He will report directly to FDA Commissioner Robert Califf.

The "Cancer Moonshot" initiative was announced by President Barack Obama at his State of the Union address in January.

Biden outlined a slew of other collaborations and initiatives, including making it easier for patients to find and enter clinical trials through the creation of a cancer trials website and making it easier for scientists to focus on research and less on raising money.

"We have to change the culture that turns scientists into grant writers," he said. "We have to reward teamwork."

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.